NR3C2 and chronic kidney disease: Small trials demonstrating renal benefits of MR blockade in animal models of kidney disease [104, 105], and of steroidal MRA on reducing proteinuria in patients with CKD [106, 107], prompted optimism surrounding their potential use in nephrology [108].